Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Christian Sieder"'
Autor:
Uta Kiltz, Xenofon Baraliakos, Jan Brandt-Jürgens, Ulf Wagner, Sebastian Lieb, Christian Sieder, Christian Mann, Jürgen Braun
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 16 (2024)
Background: Radiographic axial spondyloarthritis (r-axSpA), formerly known as ankylosing spondylitis (AS), is a chronic, inflammatory rheumatic disease associated with symptoms such as inflammatory back pain, morning stiffness, and arthritis. First-l
Externí odkaz:
https://doaj.org/article/9158e3f810f546e2ad82479d9c7d72a1
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenumab with topiramate in
Externí odkaz:
https://doaj.org/article/296c59d700ca425395985865d1cae724
Autor:
Nils Venhoff, Wolfgang A. Schmidt, Peter Lamprecht, Hans-Peter Tony, Christine App, Christian Sieder, Carolin Legeler, Claudia Jentzsch, Jens Thiel
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-15 (2021)
Abstract Background One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induct
Externí odkaz:
https://doaj.org/article/f4928bfde2514182945142901f3a3fe2
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Forced expiratory volume in 1 second (FEV1) is the only parameter currently recognized as a surrogate endpoint in cystic fibrosis (CF) trials. However, FEV1 is relatively insensitive to changes in the small airways of patients wit
Externí odkaz:
https://doaj.org/article/744d7bf22d754c18b1871fe901e8cd2f
Autor:
Sonja Ständer, Sabine Steinke, Matthias Augustin, Dieter Metze, Karin Loser, Daniel Baeumer, Christian Sieder, Thomas Luger
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 12, Pp 1085-1090 (2019)
Chronic pruritus is a bothersome symptom in psoriasis vulgaris and can profoundly reduce quality of life (QoL). In this exploratory analysis of the PSORITUS study, the impact of pruritus on QoL in 130 subjects with moderate-to-severe psoriasis was as
Externí odkaz:
https://doaj.org/article/9096a2eed5fe44a8a1819941fd244b9b
Autor:
Nils Venhoff, Wolfgang A Schmidt, Raoul Bergner, Jürgen Rech, Leonore Unger, Hans-Peter Tony, Stephanie Finzel, Ioana Andreica, David M Kofler, Stefan M Weiner, Peter Lamprecht, Hendrik Schulze-Koops, Christine App, Effie Pournara, Meryl H Mendelson, Christian Sieder, Meron Maricos, Jens Thiel
Publikováno v:
The Lancet Rheumatology. 5:e341-e350
Autor:
Wolfgang A. Schmidt, Peter Lamprecht, Carolin Legeler, Christian Sieder, Christine App, Claudia Jentzsch, Hans-Peter Tony, Jens Thiel, Nils Venhoff
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-15 (2021)
Trials
Trials
Background One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and m
Autor:
Ulrich Mrowietz, Kristian Reich, J Früh, Michael Sticherling, Christian Sieder, T. Bachhuber, Andreas Körber
Publikováno v:
British Journal of Dermatology. 184:849-856
BACKGROUND Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin-17A and shows long-lasting efficacy and safety in plaque psoriasis. More evidence is required to optimize secukinumab dosing according to clinical re
Autor:
Esteban Daudén, Aldo Cuccia, Jean-Luc Perrot, Piotr Jagiello, Ulrich Mrowietz, Matthias Augustin, Sven Gathmann, Roberto Orsenigo, Maria Polina Konstantinou, Christian Sieder, Sascha Gerdes, Külli Kingo, T. Bachhuber, Michael Rissler, Jacek C Szepietowski
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 35:431-440
Introduction Psoriatic disease is associated with considerable impairment of quality of life (QoL). The PROSE study (NCT02752776) investigated the impact of secukinumab treatment on patient-reported outcomes (PRO) in patients with moderate to severe
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Forced expiratory volume in 1 second (FEV1) is the only parameter currently recognized as a surrogate endpoint in cystic fibrosis (CF) trials. However, FEV1 is relatively insensitive to changes in the small airways of patients with milder